AbbVie Inc (ABBV)vs10X Genomics Inc (TXG)
ABBV
AbbVie Inc
$249.46
-0.54%
HEALTHCARE · Cap: $430.82B
TXG
10X Genomics Inc
$56.09
-3.54%
HEALTHCARE · Cap: $7.31B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 10337% more annual revenue ($64.39B vs $616.91M). ABBV leads profitability with a 9.8% profit margin vs -12.2%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
TXG
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.0%
Fair Value
$151.19
Current Price
$249.46
$98.27 premium
Margin of Safety
+65.9%
Fair Value
$56.16
Current Price
$56.09
$0.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 8.9x book value
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : TXG
The primary concerns for TXG are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while TXG is a turnaround play — different risk/reward profiles.
TXG carries more volatility with a beta of 2.04 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 20/100) and 10.2% revenue growth. TXG offers better value entry with a 65.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?